{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:19:22Z","timestamp":1790248762870,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\u03b2-Thalassemias are characterized by reduced production of \u03b2-globin chain, resulting in \u03b1\/\u03b2-chain unbalance and precipitation of \u03b1-globin\u2013heme complexes and determining ineffective erythropoiesis. Ineffective erythropoiesis, chronic hemolytic anemia, and compensatory hematopoietic expansion are the disease hallmarks, and they are related to the severity of the chain unbalance. Several clinical forms of \u03b2-thalassemia, including the coinheritance of \u03b2-thalassemia with hemoglobin E resulting in hemoglobin E\/\u03b2-thalassemia, have been described. Clinically, \u03b2-thalassemias can be classified as transfusion-dependent thalassemia (TDT) and non\u2013transfusion-dependent thalassemia (NTDT) according to the severity of the phenotype, which is caused by a wide spectrum of mutations in a homozygous or compound heterozygous state. Current treatment of TDT consists of regular transfusions that lead to iron overload, requiring iron chelation to prevent iron-related organ toxicity. NTDT patients do not require transfusions or only occasionally require them; however, they develop iron overload as well because of increased intestinal iron absorption caused by chronic anemia. Hematopoietic stem cell allogenic transplant is the only approved cure for \u03b2-thalassemia; however, it is still limited by clinical conditions and the availability of matched donors as well as by potential graft-versus-host disease (GVHD). Gene therapy could avoid the GVHD risk, although hematopoietic stem cells must be genetically modified ex vivo. Epigenetic manipulation and genomic editing are novel experimental approaches. An increased understanding of the pathophysiology that controls the disease process prompted us to explore alternative therapeutic approaches that address the underlying chain unbalance, ineffective erythropoiesis, and iron dysregulation. Molecules, such as JAK2 inhibitors and the activin-receptor ligand trap that target ineffective erythropoiesis, are already in clinical trials with promising results. Other agents aimed to generate iron-restricted erythropoiesis are also under experimental evaluation.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.278","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["New therapeutic targets in transfusion-dependent and -independent thalassemia"],"prefix":"10.1182","volume":"2017","author":[{"given":"M. Domenica","family":"Cappellini","sequence":"first","affiliation":[{"name":"Fondazione IRCCS, C\u00e0 Granda Policlinico, Milan, Italy; and"},{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Motta","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS, C\u00e0 Granda Policlinico, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2019111703584832200_B1","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111703584832200_B2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/35066048","article-title":"Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias","volume":"2","author":"Weatherall","year":"2001","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2019111703584832200_B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2141.2001.02482.x","article-title":"Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes","volume":"112","author":"Tavazzi","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111703584832200_B4","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","article-title":"Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin","volume":"109","author":"Gardenghi","year":"2007","journal-title":"Blood"},{"key":"2019111703584832200_B5","author":"Cappellini","year":"2014"},{"key":"2019111703584832200_B6","author":"Taher","year":"2013"},{"issue":"10","key":"2019111703584832200_B7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","article-title":"Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study","volume":"115","author":"Taher","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111703584832200_B8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.24674","article-title":"Transplantation in thalassemia: revisiting the Pesaro risk factors 25 years later","volume":"92","author":"Angelucci","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111703584832200_B9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MOH.0000000000000280","article-title":"Transplantation for thalassemia major: alternative donors","volume":"23","author":"Locatelli","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"23","key":"2019111703584832200_B10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.201.201","article-title":"Update of results from the Northstar Study (HGB-204): a phase 1\/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector (LentiGlobin BB305 drug product) [abstract]","volume":"126","author":"Walters","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111703584832200_B11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ymthe.2017.03.024","article-title":"Gene therapy for \u03b2-hemoglobinopathies","volume":"25","author":"Cavazzana","year":"2017","journal-title":"Mol Ther"},{"issue":"4","key":"2019111703584832200_B12","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.3324\/haematol.2016.154740","article-title":"Plerixaform and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixaform alone","volume":"102","author":"Liddonici","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2019111703584832200_B13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703584832200_B14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/mt.2015.113","article-title":"miRNA-embedded shRNAs for lineage-specific BCL11A knockdown and hemoglobin F induction","volume":"23","author":"Guda","year":"2015","journal-title":"Mol Ther"},{"issue":"10","key":"2019111703584832200_B15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nmeth.3554","article-title":"Functional footprinting of regulatory DNA","volume":"12","author":"Vierstra","year":"2015","journal-title":"Nat Methods"},{"issue":"8","key":"2019111703584832200_B16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood-2016-01-691089","article-title":"Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers","volume":"128","author":"Breda","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111703584832200_B17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/ng.630","article-title":"Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin","volume":"42","author":"Borg","year":"2010","journal-title":"Nat Genet"},{"issue":"4","key":"2019111703584832200_B18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI71520","article-title":"HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers","volume":"124","author":"Stadhouders","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111703584832200_B19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cell.2014.05.050","article-title":"Reactivation of developmentally silenced globin genes by forced chromatin looping","volume":"158","author":"Deng","year":"2014","journal-title":"Cell"},{"issue":"5","key":"2019111703584832200_B20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.14194","article-title":"Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease","volume":"174","author":"Liang","year":"2016","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111703584832200_B21","article-title":"Metformin induces FOXO3-dependent fetal hemoglobin production in primary erythroid cells [abstract]","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"2019111703584832200_B22","article-title":"Molecular basis of \u03b2-thalassemia and potential therapeutic targets [published online ahead of print 20 June 2017]","volume-title":"Blood Cells Mol Dis","author":"Thein"},{"issue":"4","key":"2019111703584832200_B23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3324\/haematol.2014.114827","article-title":"\u03b2-Thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies","volume":"100","author":"Rivella","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2019111703584832200_B24","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111703584832200_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.852.852","article-title":"Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from single-arm, multicenter, phase 2a truth study [abstract]","volume":"128","author":"Aydinok","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111703584832200_B26","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine \u03b2-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111703584832200_B27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"22","key":"2019111703584832200_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2439.2439","article-title":"Genetic investigation of the role of GDF11 in the treatment of \u03b2-thalassemia and MDS [abstract]","volume":"128","author":"Oikonomidou","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111703584832200_B29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"22","key":"2019111703584832200_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.851.851","article-title":"Luspatercept increases hemoglobin, decreases transfusion burden and improves iron overload in adults with beta-thalassemia [abstract]","volume":"128","author":"Piga","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111703584832200_B31","first-page":"17","article-title":"Interim results from a phase 2A, open-label, dose-finding study of sotatercept (ACE-011) in adult patients (PTS) with beta-thalssemia [abstract]","volume":"100","author":"Cappellini","year":"2015","journal-title":"Haematologica"},{"key":"2019111703584832200_B32"},{"issue":"suppl 1","key":"2019111703584832200_B33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12505","article-title":"The mutual control of iron and erythropoiesis","volume":"38","author":"Camaschella","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2019111703584832200_B34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.phrs.2016.11.010","article-title":"Therapeutic potential of hepcidin - the master regulator of iron metabolism","volume":"115","author":"Vyoral","year":"2017","journal-title":"Pharmacol Res"},{"issue":"2","key":"2019111703584832200_B35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111703584832200_B36","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2015-11-681494","article-title":"Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice","volume":"127","author":"Nai","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111703584832200_B37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.2073","article-title":"Transferrin therapy ameliorates disease in beta-thalassemic mice","volume":"16","author":"Li","year":"2010","journal-title":"Nat Med"},{"issue":"9813","key":"2019111703584832200_B38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","article-title":"Thalassaemia","volume":"379","author":"Higgs","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"2019111703584832200_B39","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.3324\/haematol.2016.155655","article-title":"Selective silencing of \u03b1-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of \u03b2-thalassemia","volume":"102","author":"Mettananda","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019111703584832200_B40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.24530","article-title":"2017 Clinical trials update in new treatments of \u03b2-thalassemia","volume":"91","author":"Makis","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111703584832200_B41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/13543784.2017.1335709","article-title":"Investigational drugs in phase I and phase II clinical trials for thalassemia","volume":"26","author":"Motta","year":"2017","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/278\/1249591\/hem00038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/278\/1249591\/hem00038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:59:07Z","timestamp":1573963147000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/278\/21053\/New-therapeutic-targets-in-transfusiondependent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.278","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}